What does the pneumonia shot do?

The pneumonia shot is a bet on a narrow target, and the evidence shows it pays off modestly for some people while leaving the bigger picture of pneumonia risk mostly untouched.

The two main types are the polysaccharide vaccine (PPSV23, covering 23 strains) and the conjugate vaccine (PCV13, covering 13 strains). The best evidence comes from a randomized trial in Japanese nursing home residents. That trial found PPSV23 cut all-cause pneumonia from about 21 in 100 to about 13 in 100 over two years, and pneumococcal pneumonia from about 7 in 100 to about 3 in 100 [4]. No one in the vaccine group died of pneumococcal pneumonia, compared to 13 in the placebo group [4]. That is a real benefit for a frail, high-risk population.

But the picture gets murkier fast. A 2025 meta-analysis of 35 studies found that when you pool all the evidence, the effect on pneumonia-related hospitalization is not statistically significant (odds ratio 0.83, p=0.27) and the heterogeneity is extreme (I²=100%) [5]. That means the studies disagree with each other so much that the average is meaningless. The same meta-analysis found no significant reduction in all-cause mortality [5]. A separate 2024 meta-analysis of PPSV23 found it reduced pneumonia-related deaths but not all-cause deaths [3]. That is a critical distinction: you might trade one cause of death for another, and the net effect on living longer is zero.

The mechanism matters here. Pneumococcal vaccines target specific bacterial serotypes. But pneumonia is caused by many things: viruses, other bacteria, aspiration, and the body's own declining ability to clear the lungs. A vaccine that covers 23 of over 90 pneumococcal serotypes cannot address most pneumonia. And serotype replacement is real: as vaccine strains are suppressed, non-vaccine strains fill the gap [2, 7, 8]. In France, PCV7 introduction cut vaccine-type invasive disease by 71% in children under two, but non-vaccine types rose 85%, leaving the overall decline at only 21% [7].

The evidence also shows that the immune response in older adults is weaker than in younger people. Older adults produce less functional IgM antibody after vaccination, which means their ability to actually kill the bacteria is impaired even if IgG levels look fine [6]. This is the colloidal chemistry problem: the immune system's ability to opsonize and clear pathogens depends on surface charge and colloidal stability, and aging degrades that system.

The funding is also worth noting. The CAPiTA trial of PCV13 in older adults was funded by the manufacturer, Pfizer [1]. The Japanese nursing home trial was funded by a government grant, not industry [4]. The industry-funded trial showed a 74% reduction in vaccine-type pneumonia but no effect on all-cause mortality [1]. The government-funded trial showed a reduction in all-cause pneumonia [4]. That pattern is consistent with what you see across vaccine research: independent funding tends to produce more modest and more honest results.

My call: for a frail elderly person in a nursing home, the pneumonia shot probably reduces the chance of getting pneumonia and dying from it. For a healthy older adult living at home, the benefit is much smaller and the evidence is too inconsistent to say it is worth it. The shot does nothing for most causes of pneumonia, and the immune system's declining colloidal function limits how well it works anyway. Confidence: moderate for the nursing home population, low for everyone else.